US-based cancer-treatment startup Erasca has raised $200 million in its Series B round led by ARCH Venture Partners and Cormorant Asset Management, the company said in a statement Monday.
New investors in the round include Singapore government-linked entity EDBI, Invus, Terra Magnum Capital Partners and other private and strategic investors, Erasca said, adding that existing investors City Hill Ventures, Colt Ventures and LifeSci Venture Partners also participated in the round.
